Last checked at 13 Mar 2024 17:32
13 MARCH 2024
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Block Listing Return
Name of applicant: | Oncimmune Holdings plc
|
Name of scheme: | Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans
|
Period of return: | 15 March 2022 to 12 March 2024
|
Balance of unallotted securities under scheme(s) from previous return:
| 5,787,346 |
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
| 0 |
Less: Number of securities issued/allotted under scheme(s) during period:
| 108,882 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
| 5,678,464 |
For further information:
Oncimmune Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com